Healthcare Polish Investing Ideas

SNT logo
Synektik Spólka Akcyjna

Cardiac marker could be a hit

In 5 years, the company should still be thriving, entering new markets and expanding in existing ones. Positive passage of the third stage of testing of a new cardiac marker could help.Read more

View narrative
212
users have viewed this narrative
1users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
zł204.19
45.8% overvalued intrinsic discount
Phetuvov's Fair Value
Revenue
8.49% p.a.
Profit Margin
13%
Future PE
22x
Price in 2029
zł311.79